Schedule-Dependent Combined Sensitivity Testing of Anti-Cancer Agents in Human Gastric Carcinoma Cell Lines
- 1 June 2001
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 29 (3) , 189-197
- https://doi.org/10.1177/147323000102900306
Abstract
The efficacy of combination chemotherapy for gastric carcinoma has been unsatisfactory, although the prognosis of advanced and recurrent disease has improved with the introduction of cisplatin (CDDP). This study examines the effect of the anti-cancer therapies CDDP, doxorubicin (ADM) and etoposide (VP-16) on the cell cycle and their cytotoxicity against two gastric carcinoma cell lines: MKN-28 (well differentiated) and MKN-45 (poorly differentiated). The treatments have different cytocidal mechanisms, and they were studied in dual combinations. For all combinations studied, cytotoxicity against MKN-45 was higher than against MKN-28. For ADM plus CDDP, or ADM plus VP-16, cytotoxicity was higher in patients pretreated with ADM than other regimens. The highest anti-tumour activity against both cell lines was obtained with ADM followed by CDDP (we have obtained good clinical results with this regimen). Schedule-dependent combined sensitivity testing of anti-cancer agents will be useful for the clinical application of therapiesKeywords
This publication has 25 references indexed in Scilit:
- Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitroBritish Journal of Cancer, 1996
- Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell linesBritish Journal of Cancer, 1996
- Chemotherapy of gastric cancerAnti-Cancer Drugs, 1996
- Feasibility Study on Protracted Infusional 5-Fluorouracil and Consecutive Low-Dose Cisplatin for Advanced Gastric CancerOncology, 1996
- A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancerCancer, 1993
- Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomyCancer, 1992
- Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trialAnnals of Oncology, 1991
- Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.Journal of Clinical Oncology, 1991
- 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric CancerAnnals of Internal Medicine, 1980
- The Use of Drugs in Combination for the Treatment of CancerNew England Journal of Medicine, 1973